Pathos AI Raises $365 Million to Build the World’s Largest Oncology AI Model
Pathos AI Inc., a biotech startup using artificial intelligence to develop oncology drugs, has raised $365 million in a late-stage Series D funding round. The raise values the company at $1.6 billion, further cementing its position as a key player in AI-driven cancer research.
Though Pathos did not reveal the round's investors, FierceBiotech reported participation from both new and existing backers. The startup has previously attracted investment from NEA, General Atlantic, and other institutional firms.
AI That Understands Cancer
At the core of Pathos’ mission is its proprietary platform, PathOS. The system hosts petabytes of oncology and genomic data, enabling scientists to streamline the drug development process. Researchers can leverage the platform to analyze clinical trials, identify novel biomarkers, and design better treatment pathways.
Currently, the company is conducting trials for two oncology drug candidates licensed from Novo Nordisk and Prelude Therapeutics. The new funding will support these trials and help build what Pathos claims will be the largest AI foundation model in oncology.
Also read: Gradiant Rolls Out AI Water Solutions for Data Centers in US and Indo-Pacific
The upcoming model will process multimodal data—including clinical, molecular, and imaging information. It aims to make clinical trial design more effective, while also simplifying biomarker discovery and other complex research tasks.
A $200 Million Data Partnership with Tempus and AstraZeneca
In April, Pathos partnered with AstraZeneca and Tempus AI Inc. to accelerate model training. Tempus, which went public in a $410 million IPO last year, is providing anonymized oncology datasets. The collaboration includes $200 million in data licensing and development agreements.
Competing in a Fast-Growing Field
Other tech giants are also entering the space. In March, Google unveiled TxGemma, a language model optimized for drug development. Microsoft, meanwhile, introduced TamGen, designed to automate molecular discovery.
Pathos stands out by focusing solely on oncology and combining clinical, genomic, and imaging data at scale.
With billions in backing, elite partnerships, and a growing pipeline, Pathos is well-positioned to shape the future of AI-powered cancer treatment.
